LEPU BIO (02157) has announced that its clinical trial results, including the Phase III study of CMG901, have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. Specifically, the company will present four sets of clinical findings at the upcoming conference.
First, the positive results from the Phase III clinical trial of CMG901 in patients with Claudin 18.2-positive advanced or metastatic gastroesophageal cancer (GEC) who have received second-line or later (2L+) treatment have been selected as a Late-Breaking Abstract (LBA) and will be presented as a preferred paper during the Presidential Symposium. Second, the positive Phase I clinical data for MRG007, a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC), have also been selected as an LBA and will be delivered via rapid oral presentation. Third, positive results from a European Phase II study evaluating the combination of MRG003 and HX008 in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for rapid oral presentation. Fourth, positive findings from a Phase II study of MRG003 in combination with HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic or poorly differentiated thyroid cancer will also be presented in a rapid oral session.
The 2026 ESMO Congress is scheduled to take place from October 23 to 27, 2026, in Madrid, Spain. Recognized as one of the largest, most academically rigorous, and most authoritative oncology conferences globally, the ESMO Congress brings together leading experts, clinicians, and clinical researchers from around the world to exchange advanced therapeutic concepts and cutting-edge clinical and translational research developments in cancer care.
CMG901 (AZD0901) is a CLDN18.2-targeting ADC developed jointly by the company and KeyMed Biosciences. In February 2023, the global rights for the research, development, registration, manufacturing, and commercialization of CMG901 were licensed to AstraZeneca. The detailed results of the Phase III trial of CMG901 in patients with 2L+ advanced or metastatic Claudin 18.2-positive GEC will be unveiled for the first time as an LBA during the ESMO Presidential Symposium. Additionally, the Phase I clinical data for MRG007, a potential best-in-class ADC targeting CDH17 for the treatment of gastrointestinal malignancies, will also be disclosed for the first time at the 2026 ESMO Congress in the form of an LBA rapid oral presentation.
Comments